Table 4.

Number (%) of subjects with adverse events reported during treatment with dabigatran etexilate (excluding washout periods)

	Treatment periods
	DE alone	DE plus rifampicin	Rifampicin
Number of subjects (%)	24 (100)	24 (100)	24 (100)
Any AE	2 (8.3)	4 (16.7)	2 (8.3)
Severe AEs	0	0	0
Drug-related AEs	0	0	1 (4.2)
Other significant AEs	0	0	0
AEs leading to discontinuation	0	0	0
Serious AEs	0	0	0

Abbreviations: AE, adverse event; and DE, dabigatran etexilate.